Clinical Trial

Clinical Evaluation of Montelukast in Veterans With Gulf War Illness

Study acronym: (GWI)
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The study addresses the pre-clinical promise of Montelukast (MLK) for improving brain function in veterans with Gulf War Illness (GWI). MLK, a US Food and Drug administration (FDA)-approved drug for asthma, has shown efficacy in an animal model of GWI to improve cognitive and mood function through modulation of leukotriene signaling and suppression of neuroinflammation.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2023-08-07; most recent amendment 2025-08-15.
Status change: Not Yet Recruiting → Recruiting 2025-08-15
Trial Details
NCT Number NCT05992311
Lead Sponsor Baylor College of Medicine
Collaborators: Michael E. DeBakey VA Medical Center, Texas A&M University
Conditions Gulf War Syndrome
Enrollment 80 participants
Start Date 2025-08-15
Primary Completion 2028-04 (estimated)
Study Completion 2028-08 (estimated)
Updated on ClinicalTrials.gov 2025-08-20